TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

Targeted Therapy

Health Care Sector Icon
Life sciences investment banking

Why is targeted therapy a focus theme in 2020?


What is driving the resurgence of targeted therapies in oncology?

As tumor genomic profiling is becoming more common, investment in the capabilities to develop precision medicines against new targets and mechanisms of resistance should strengthen oncology strategy. Significant acquisitions and promising data fueled investor sentiment in 2019, and we expect continued focus on targeted therapy into 2020.

Increasingly robust understanding of the genetic mutations driving certain cancers partially de-risks the development of targeted oncology, which appeals to many investors and potential acquirers. Moreover, there will be catalysts in 2020, including potential approval and launch of a new drug in Triple Negative Breast Cancer, which alone could exceed $1 billion in sales over the next few years, in our view.

What we’re watching:

  • Capmatinib
  • KRAS
  • Sacituzumab
  • Selpercatinib
  • M&A
Themes 2020

15 Themes to Focus on 2020: A Handbook for Portfolio Managers

Download the Handbook

Expected overall sales of targeted therapies in 2023


Estimated TAM for kras g12c inhibitors in 2022


Average overall response rate of patients treated with targeted therapies in 1L, 1L ALK+, 1L EGFR+, 1L ROS+ and 1L RET+ Settings vs. Chemo or Immuno Therapies


Percentage of human cancers activated by ras mutation


The US Capital building under a bright blue sky.

The Big Three For 2024- Presidential, Congress, & Policy Implications

The Gherkin sky scrapper in financial district in London.

The Current State of Liquidity in European Markets

US flags blowing in the wind.

A Tale Of Two Budgets: The New FY25 DoD Budget Is Out With Congress Still Closing The Book On FY24


New York, NY

Jun 04, 2024

8th Annual Future of the Consumer Conference

New York, NY

May 29, 2024

52nd Annual Technology, Media & Telecom Conference


Mar 19, 2024

3rd Annual Fiber-to-the-Home Symposium